Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871311 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
A Phase 1 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01871311: Clinical Trial Phase 1 study, sponsored by Georgetown University.
NCT01871311 is a Phase 1 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01871311, a Phase 1 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.
Primary Outcome
The dose at which \</= 1 out of 6 subjects experiences a dose limiting toxicity
Interventions
- DRUG Nilotinib + Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Why NCT01871311 stopped before completion
NCT01871311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Nilotinib + Cetuximab is the first listed.
NCT01871311 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01871311 about?
NCT01871311 is a clinical study titled "A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors". The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.
What is the current status of trial NCT01871311?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01871311?
The interventions under investigation include: Nilotinib + Cetuximab (DRUG).
Who is sponsoring clinical trial NCT01871311?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01871311's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia